Holen Sie sich die Stockscreener-App
24.34
3.88%
0.91
Handel nachbörslich:
24.34
Schlusskurs vom Vortag:
$23.43
Offen:
$23.94
24-Stunden-Volumen:
1.35M
Relative Volume:
0.77
Marktkapitalisierung:
$1.95B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-11.32
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
+1.00%
1M Leistung:
-7.59%
6M Leistung:
+283.31%
1J Leistung:
+479.52%
1-Tages-Spanne:
$23.53
$24.70
1-Wochen-Bereich:
$22.88
$25.17
52-Wochen-Spanne:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
24.34 | 1.88B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olma Health (NASDAQ: OLMA) director reports several stock sales in Jan–Feb 2026 - Stock Titan
Insider sells 15,000 OLMA shares; 25,000-share option sale planned (OLMA) - Stock Titan
OLMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
How Leadership Turnover and Palazestrant Optimism At Olema Pharmaceuticals (OLMA) Has Changed Its Investment Story - Sahm
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals CEO to join TDCowen Health Care Conference fireside chat in Boston - Traders Union
Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference - MarketBeat
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors - Yahoo Finance
OLMA Should I Buy - Intellectia AI
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure - Yahoo Finance
Olema earnings on deck: Biotech faces widening loss ahead of key data - Investing.com South Africa
Olema Pharmaceuticals, Inc. (OLMA): Investor Outlook on a Promising Biotech with 91% Potential Upside - DirectorsTalk Interviews
20,000-share Form 144 filed for Olami Medical (NASDAQ: OLMA) - Stock Titan
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit - MarketBeat
Shane Kovacs sells 110,000 OLMA shares across Jan–Feb 2026 (NASDAQ: OLMA) - Stock Titan
OLMA (NASDAQ: OLMA) Form 144 shows proposed 20,000-share sale; prior insider sales listed - Stock Titan
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
OLMA Technical Analysis & ETF Price Forecast - Intellectia AI
Aug Drivers: Can JetBlue Airways Corporation reach resistance levels soonQuarterly Profit Report & Risk Managed Investment Signals - baoquankhu1.vn
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One‑Year Surge? - Yahoo Finance
Olema Pharmaceuticals (OLMA) sees 9.99% stake from Bain Capital - Stock Titan
Olema Nears Palazestrant Readout As Commercial Shift Raises Execution Risks - Yahoo Finance
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating - Yahoo Finance
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity? - Intellectia AI
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit - MarketBeat
Published on: 2026-02-14 18:42:21 - mfd.ru
Is Olema (OLMA) Balancing Leadership Change and New Wall Street Attention to Refine Its Strategy? - Sahm
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) with B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Stifel Nicolaus Initiates Coverage on Olema Pharmaceuticals With Buy Rating - marketscreener.com
Candriam S.C.A. Increases Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Stifel initiates coverage of Olema Pharmaceuticals (OLMA) with buy recommendation - MSN
Will Olema Pharmaceuticals Inc. stock benefit from automationJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - mfd.ru
Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Olema Oncology to Participate in Upcoming Investor Conferences - Sahm
Olema Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Olema Pharmaceuticals seeks NDA lead for biotech program - Traders Union
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Weekly Recap: Does Olema Pharmaceuticals Inc have pricing power2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Institutional Investors Control 63% of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) and Were Rewarded Last Week After Stock Increased 7.2% - 富途牛牛
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Investment Review: Is Olema Pharmaceuticals Inc stock trending bullishQuarterly Trade Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Pfizer-Olema Collaboration Targets Metastatic Breast Cancer - MSN
Olema Pharmaceuticals to Present at Upcoming Investor Conferences in February 2026 - Quiver Quantitative
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):